Outcomes and prognostic factors in angioimmunoblastic T cell lymphoma: final report from the International TCell Project
Authors
Advani, R.Skrypets, T.
Civallero, M.
Spinner, M. A.
Manni, M.
Kim, W.
Shustov, A.
Horwitz, S. M.
Hitz, F.
Cabrera, M. E.
Dlouhy, I.
Vassallo, J.
Pileri, S. A.
Inghirami, G. G.
Montoto, S.
Vitolo, U.
Radford, John A
Vose, J.
Federico, M.
Affiliation
Stanford University, Stanford, California, United StatesIssue Date
2021
Metadata
Show full item recordAbstract
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary endpoints were 5-year overall survival (OS) and progression-free survival (PFS), respectively. We analyzed the prognostic impact of clinical covariates and progression of disease within 24 months (POD24) and developed a novel prognostic score. The median age was 64 years, and 90% of patients had advanced stage disease. Eighty-one percent received anthracycline-based regimens and 13% underwent consolidative autologous stem cell transplant (ASCT) in first complete remission (CR1). Five-year OS and PFS estimates were 44% and 32%, respectively, with improved outcomes for patients who underwent ASCT in CR1. In multivariate analysis, age ³60 years, ECOG performance status >2, elevated C-reactive protein, and elevated β2 microglobulin were associated with inferior outcomes. A novel prognostic score (AITL score) combining these factors defined low, intermediate, and high-risk subgroups with 5-year OS estimates of 63%, 54%, and 21%, respectively, with greater discriminant power than established prognostic indices. Finally, POD24 was a powerful prognostic factor with 5-year OS of 63% for patients without POD24 compared to only 6% for patients with POD24 (p<0.0001). These data will require validation in a prospective cohort of homogeneously treated patients. Optimal treatment of AITL continues to be an unmet need and novel therapeutic approaches are required.Citation
Advani R, Skrypets T, Civallero M, Spinner MA, Manni M, Kim W, et al. Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. Blood. 2021.Journal
BloodDOI
10.1182/blood.2020010387PubMed ID
33786592Additional Links
https://dx.doi.org/10.1182/blood.2020010387Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood.2020010387